{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:30:56Z","timestamp":1794353456475,"version":"4.9.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi260916-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a leading cause of hospitalization among infants. Nirsevimab, a long-acting monoclonal antibody that protects against severe RSV, was publicly funded for all infants in the Canadian provinces of Ontario and Quebec starting in the fall of 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260916-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate the clinical effectiveness of nirsevimab at preventing RSV-related emergency department (ED) visits, inpatient hospitalizations, and intensive care unit (ICU) admissions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260916-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This test-negative case-control study obtained data from 7 tertiary care pediatric hospitals located in Ontario and Quebec, Canada, that are members of the Surveillance Program for the Rapid Identification and Tracking of Infectious Diseases in Kids (SPRINT-KIDS) Project. Symptomatic infants younger than 12 months who were tested for RSV in the ED, inpatient units, or ICUs of participating institutions between October 27, 2024, and March 1, 2025, were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260916-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Receipt of nirsevimab 7 days or more prior to RSV test date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260916-8\">\n                    <jats:title>Main Outcome and Measure<\/jats:title>\n                    <jats:p>The primary outcome was laboratory-confirmed RSV infection. Participants were stratified by disposition outcome\u2014ED visit only, hospitalization, or ICU admission\u2014on the day of specimen collection or within the subsequent 14 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260916-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 1942 eligible encounters in infants (median [IQR] age, 3.0 [1.9-5.6] months; 1110 males [57.2%]) who were tested for RSV, 683 (35.2%) had RSV-positive test results (cases) and 1259 (64.8%) had RSV-negative test results (controls). Overall, 429 infants (22.1%) received nirsevimab. A lower proportion of cases than controls received nirsevimab (7.0% [48 of 683] vs 30.3% [381 of 1259];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Adjusted nirsevimab effectiveness against laboratory-confirmed RSV was estimated to be 78% (95% CI, 68%-84%), including 77% (95% CI, 62%-86%) against ED visits, 79% (95% CI, 66%-87%) against hospitalizations, and 97% (95% CI, 85%-100%) against ICU admissions. Effectiveness remained high across all subgroups, including premature infants (90% [95% CI, 66%-98%]), those with comorbidities (86% [95% CI, 37%-98%]), and time from receipt (85% [95% CI, 75%-92%]); results of sensitivity analyses were consistent with those of primary analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260916-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This test-negative case-control study found that administration of nirsevimab to infants had high estimated effectiveness in preventing RSV disease severity that requires hospital-based care. The results suggest that nirsevimab has the potential to reduce the burden of RSV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.33621","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:00:59Z","timestamp":1789398059000},"page":"e2633621","source":"Crossref","is-referenced-by-count":2,"title":["Respiratory Syncytial Virus\u2013Related Hospitalizations Among Infants Receiving Nirsevimab"],"prefix":"10.1001","volume":"9","author":[{"given":"Sarah A.","family":"Buchan","sequence":"first","affiliation":[{"name":"Communicable Disease Control, Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maala","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine, Children\u2019s Hospital of Eastern Ontario, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Papenburg","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children\u2019s Hospital, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Mark","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, British Columbia Children\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Pernica","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Burstein","sequence":"additional","affiliation":[{"name":"Montreal Children\u2019s Hospital, Division of Pediatric Emergency Medicine, McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Gravel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Emergency Medicine, Centre Hospitalier Universitaire Sainte-Justine, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Berthelot","sequence":"additional","affiliation":[{"name":"D\u00e9partement de M\u00e9decine de Famille et de M\u00e9decine d\u2019Urgence, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April J.","family":"Kam","sequence":"additional","affiliation":[{"name":"Division of Pediatric Emergency Medicine, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Poonai","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada"},{"name":"Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Eltorki","sequence":"additional","affiliation":[{"name":"Section of Pediatric Emergency Medicine, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Section of Pediatric Emergency Medicine, Department of Emergency Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"Divisions of Paediatric Emergency Medicine and Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Sabhaney","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine, Department of Pediatrics, and British Columbia Children\u2019s Hospital Research Institute, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Gill","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Dickinson","sequence":"additional","affiliation":[{"name":"Departments of Family Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Communicable Disease Control, Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario Canada"},{"name":"Populations and Public Health Research Program, ICES, Toronto, Ontario, Canada"},{"name":"Department of Family and Community Medicine, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Section of Pediatric Emergency Medicine, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Section of Pediatric Emergency Medicine, Department of Emergency Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Section of Gastroenterology, Departments of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SPRINT-KIDS Project Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Orr","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mahant","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mater","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Ali","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy","family":"Beer","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dixon","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh","family":"Doan","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Emsley","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Khan","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Lu","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archna","family":"Shah","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Wright","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Vanderkooi","sequence":"additional","affiliation":[{"name":"for the SPRINT-KIDS Project Team"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"issue":"9","key":"zoi260916r1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaf079","article-title":"Hospitalizations associated with respiratory syncytial virus illness among children and adolescents in Ontario, Canada.","volume":"14","author":"Goyette","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"1","key":"zoi260916r2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2556588","article-title":"Successes, lessons learned and recommendations for the future: experiences from the first year of Ontario\u2019s nirsevimab program for respiratory syncytial virus (RSV) prophylaxis in infants.","volume":"21","author":"Paes","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"zoi260916r3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/irv.12497","article-title":"Burden of influenza, respiratory syncytial virus, and other respiratory viruses and the completeness of respiratory viral identification among respiratory inpatients, Canada, 2003-2014.","volume":"12","author":"Schanzer","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"issue":"10","key":"zoi260916r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36863","article-title":"Pediatric RSV-associated hospitalizations before and during the COVID-19 pandemic.","volume":"6","author":"Bourdeau","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260916r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16077","article-title":"Pediatric respiratory syncytial virus hospitalizations, 2017-2023.","volume":"7","author":"Fitzpatrick","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi260916r6","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/infdis\/jiac120","article-title":"Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the National (Nationwide) Inpatient Sample.","volume":"226","author":"Suh","year":"2022","journal-title":"J Infect Dis"},{"key":"zoi260916r7","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1093\/infdis\/jiac155","article-title":"Respiratory syncytial virus burden and healthcare utilization in United States infants &lt;1 year of age: study of nationally representative databases, 2011-2019.","volume":"226","author":"Suh","year":"2022","journal-title":"J Infect Dis"},{"issue":"7","key":"zoi260916r8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jpids\/piad045","article-title":"Estimating the incidence of first RSV hospitalization in children born in Ontario, Canada.","volume":"12","author":"Buchan","year":"2023","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"zoi260916r9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/jpids\/piz087","article-title":"Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged &lt;2 years in the United States, 2014-15.","volume":"9","author":"Arriola","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"3","key":"zoi260916r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150416","article-title":"Incidence of hospitalization for respiratory syncytial virus infection amongst children in Ontario, Canada: a population-based study using validated health administrative data.","volume":"11","author":"Pisesky","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"zoi260916r11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260916r12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.","volume":"7","author":"Sim\u00f5es","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"22","key":"zoi260916r13","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated evidence for Covid-19, RSV, and influenza vaccines for 2025-2026.","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med"},{"key":"zoi260916r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2026.101448","article-title":"Nirsevimab effectiveness, number needed to immunize and impact on severe RSV outcomes, a test-negative study in Quebec, Canada.","volume":"57","author":"Carazo","year":"2026","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"zoi260916r18","doi-asserted-by":"publisher","first-page":"31369","DOI":"10.1038\/s41598-025-16802-y","article-title":"Predicting regional and temporal incidence of RSV and influenza hospitalizations in a birth cohort of young Australian children.","volume":"15","author":"Taye","year":"2025","journal-title":"Sci Rep"},{"issue":"4","key":"zoi260916r19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14745\/ccdr.v51i04a01","article-title":"Summary of the National Advisory Committee on Immunization (NACI) statement on the prevention of respiratory syncytial virus (RSV) in infants.","volume":"51","author":"Killikelly","year":"2025","journal-title":"Can Commun Dis Rep"},{"issue":"9","key":"zoi260916r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31499","article-title":"Clinical testing for COVID-19, influenza, and RSV in hospitalized youths, 2016-2024.","volume":"8","author":"Toepfer","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260916r21","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.","volume":"29","author":"L\u00f3pez-Lacort","year":"2024","journal-title":"Euro Surveill"},{"issue":"3","key":"zoi260916r22","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400275","article-title":"Nirsevimab effectiveness at preventing RSV-related hospitalization in infants.","volume":"4","author":"Jabagi","year":"2025","journal-title":"NEJM Evid"},{"issue":"5","key":"zoi260916r23","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.5.2400596","article-title":"Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023\/24 season.","volume":"30","author":"N\u00fa\u00f1ez","year":"2025","journal-title":"Euro Surveill"},{"key":"zoi260916r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101196","article-title":"Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis.","volume":"49","author":"Payne","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"2","key":"zoi260916r25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamapediatrics.2025.5280","article-title":"Nirsevimab against hospitalizations and emergency department visits for lower respiratory tract infection in infants: a meta-analysis.","volume":"180","author":"Sumsuzzman","year":"2026","journal-title":"JAMA Pediatr"},{"issue":"37","key":"zoi260916r26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.15585\/mmwr.mm7437a1","article-title":"Nirsevimab effectiveness against intensive care unit admission for respiratory syncytial virus in infants - 24 states, December 2024-April 2025.","volume":"74","author":"Zambrano","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"zoi260916r27","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/archdischild-2025-329005","article-title":"Effectiveness of nirsevimab against RSV-related outcomes: findings of the 2024-2025 campaign in Catalonia align with previous analysis.","volume":"110","author":"Coma","year":"2025","journal-title":"Arch Dis Child"},{"key":"zoi260916r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101443","article-title":"Effectiveness of nirsevimab against hospitalisation for RSV-bronchiolitis during high RSV-B circulation in the second year of nationwide implementation in France: a test-negative case-control study.","volume":"58","author":"Furgier","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"zoi260916r29","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70662","article-title":"Real-world effectiveness of nirsevimab in preventing RSV hospitalizations: evidence of protection in Southern Italian infants, 2024-2025.","volume":"97","author":"Fortunato","year":"2025","journal-title":"J Med Virol"},{"issue":"45","key":"zoi260916r30","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2025.30.45.2500816","article-title":"Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged &lt; 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.","volume":"30","author":"Savulescu","year":"2025","journal-title":"Euro Surveill"},{"issue":"9","key":"zoi260916r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.33535","article-title":"Nirsevimab administration and RSV hospitalization in the 2024-2025 season.","volume":"8","author":"Pelletier","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260916r32","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2025.5778","article-title":"Effectiveness and impact of maternal RSV immunization and nirsevimab on medically attended RSV in US children.","author":"Moline","year":"2026","journal-title":"JAMA Pediatr"},{"issue":"5","key":"zoi260916r34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","article-title":"Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study.","volume":"26","author":"Razzini","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"zoi260916r35","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/thorax-2025-223376","article-title":"Real-world effectiveness and safety of nirsevimab, RSV maternal vaccine and RSV vaccines for older adults: a living systematic review and meta-analysis.","volume":"80","author":"Lee","year":"2025","journal-title":"Thorax"},{"issue":"6","key":"zoi260916r36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2352-4642(25)00093-8","article-title":"Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis.","volume":"9","author":"Sumsuzzman","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"zoi260916r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106466","article-title":"Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024.","volume":"90","author":"Wadia","year":"2025","journal-title":"J Infect"},{"issue":"2","key":"zoi260916r38","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S1473-3099(24)00811-9","article-title":"Full 2023-24 season results of universal prophylaxis with nirsevimab in Galicia, Spain: the NIRSE-GAL study.","volume":"25","author":"Mallah","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"zoi260916r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103281","article-title":"Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: a systematic review and meta-analysis.","volume":"84","author":"Trusinska","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"7","key":"zoi260916r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.20440","article-title":"Nirsevimab uptake in a pediatric primary care network during the 2023-2024 RSV season.","volume":"8","author":"Schaffer DeRoo","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi260916r42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0380","article-title":"Estimated effectiveness of nirsevimab against respiratory syncytial virus.","volume":"8","author":"Xu","year":"2025","journal-title":"JAMA Netw Open"},{"key":"zoi260916r43","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819001961","article-title":"Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results.","volume":"147","author":"Lipsitch","year":"2019","journal-title":"Epidemiol Infect"},{"issue":"10","key":"zoi260916r44","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/cid\/ciy770","article-title":"Intraseason waning of influenza vaccine effectiveness.","volume":"68","author":"Ray","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zoi260916r45","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/aje\/kwac015","article-title":"Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 vaccines.","volume":"191","author":"Kahn","year":"2022","journal-title":"Am J Epidemiol"},{"issue":"11","key":"zoi260916r46","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/infdis\/jiad185","article-title":"Pediatric respiratory syncytial virus diagnostic testing performance: a systematic review and meta-analysis.","volume":"228","author":"Onwuchekwa","year":"2023","journal-title":"J Infect Dis"},{"key":"zoi260916r47","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.70219","article-title":"Low-value care and variation in practice in the care of children hospitalized with bronchiolitis in Canada (CareBEST): protocol for a multi-center prospective cohort study.","author":"Bonham","year":"2026","journal-title":"J Hosp Med"},{"key":"zoi260916r14","unstructured":"Summary basis of decision for Beyfortus. Government of Canada. Accessed December 1, 2025. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD1686249847840"},{"key":"zoi260916r16","unstructured":"The SPRINT-KIDS Project: surveillance program for the Rapid IdeNtification and TracKing of Infectious Diseases in kidS. University of Calgary. Accessed on December 1, 2025. https:\/\/cumming.ucalgary.ca\/project\/sprint-kids-0?"},{"key":"zoi260916r17","unstructured":"TCPS interpretations. Panel on Research Ethics. May 2024. Accessed December 1, 2025. https:\/\/ethics.gc.ca\/eng\/documents\/TCPS2_interpretations-en.pdf"},{"key":"zoi260916r33","doi-asserted-by":"crossref","unstructured":"Bemmo? A, Fortin? \u00c9, Fortin? P, . Impact of the first nirsevimab immunization campaign on RSV-related emergency department visits and hospitalizations in Qu\u00e9bec, Canada.? medRxiv. Preprint posted online October 21, 2025. doi:10.1101\/2025.10.20.25338243?","DOI":"10.1101\/2025.10.20.25338243"},{"key":"zoi260916r41","unstructured":"Infant RSV prevention: using data to track public health efforts. Better Outcomes Registry & Network. Accessed January 12, 2026. https:\/\/www.bornontario.ca\/initiatives-resources\/perinatal-and-paediatric-care\/respiratory-syncytial-virus\/2024-2025-rsv-season-data\/"},{"key":"zoi260916r48","unstructured":"Respiratory syncytial virus (RSV) vaccines: Canadian immunization guide. Public Health Agency of Canada.  2025. Accessed December 1, 2025. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/respiratory-syncytial-virus.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854030\/buchan_2026_oi_260916_1788542468.35542.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:01:05Z","timestamp":1789398065000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.33621","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}